OptimizeRx Q1 revenue down 5% to $13.0M; GAAP EPS loss $(0.37), non-GAAP loss $(0.09)

OptimizeRx Corp

2023-Q1 EPS reported -$0.37 revenue$13,002,910

Total revenue $13.0M, down 5% from $13.7M a year ago; gross profit $7.4M (-8% YoY).
GAAP net loss $(6.4)M or $(0.37) per share vs. $(3.8)M or $(0.21) last year.
Non-GAAP net loss $(1.6)M or $(0.09) per share vs. $(0.1)M or $(0.01) last year.
Reaffirms FY2023 guidance: net revenue growth at least 10% YoY, gross margins 58-62%.
Rolling 12-month net revenue retention fell to 86% from 124%; avg revenue per top 20 pharma co. down to ~$1.99M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OptimizeRx Corp reported the three months ended March 31, 2023 results: revenue $13.0 million, net income $(6.4) million, EPS $(0.37). Guidance reaffirmed.

Period: the three months ended March 31, 2023
Revenue: $13.0 million
Net income: $(6.4) million
EPS: $(0.37)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Financial Highlights ● Revenue in the first quarter of 2023 decreased 5% to $13.0 million, as compared to $13.7 million in the same year ago period. ● Gross profit in the first quarter of 2023 decreased 8% year-over-year to $7.4 million, from $8.1 million during the first quarter of 2022. ● GAAP net loss totaled $(6.4) million or $(0.37) per basic and diluted shares outstanding

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

OptimizeRx Corp filing history →

Source: SEC EDGAR

accession 0001213900-23-038131

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.